Results 261 to 270 of about 121,016 (287)
Some of the next articles are maybe not open access.
4-1BB Chimeric Antigen Receptors
The Cancer Journal, 2014In addition to T-cell receptor signals, T lymphocytes require costimulatory signals for robust activation. Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymphocytes as well as natural killer cells and other hematopoietic and nonhematopoietic cells.
Dario, Campana +2 more
openaire +2 more sources
Structural Determinants of Chimeric Antigen Receptor Design
Critical Reviews in Immunology, 2021Chimeric antigen receptor (CAR) T cell therapy consists of the gene transfer of a cassette encoding a receptor capable of redirecting the transduced T cell toward a specific cytotoxic response against tumor cells. The therapy has been providing a new perspective on some hematologic malignancies, such as CD19+ lymphomas and acute lympho-blastic leukemia.
Luiza, Abdo +2 more
openaire +2 more sources
Chimeric antigen receptor T-cell toxicity
Current Opinion in Pediatrics, 2019Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire +2 more sources
Imaging Chimeric Antigen Receptor (CAR) Activation
2020The chimeric antigen receptor (CAR) has been extensively exploited in cancer immunotherapy. In spite of the success of CAR T cells in clinical applications, the molecular mechanism underlying CAR-T cell activation remains unclear. Key questions remain: how are CARs activated by tumor antigens?
Kendra A, Libby, Xiaolei, Su
openaire +2 more sources
Chimeric Antigen Receptor Design Today and Tomorrow
The Cancer Journal, 2021Abstract The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as antigen-ligand binding partners and variable lymphocyte receptors.
Justin C, Boucher, Marco L, Davila
openaire +2 more sources
Chimeric antigen receptor T‐cell therapy toxicities
British Journal of Clinical Pharmacology, 2020Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor (CAR) T cells emerging as an innovative technology that harnesses the immune system to fight malignant diseases. These genetically engineered T‐cells have shown encouraging results for B‐cell lymphoid malignancies and are now being explored for other cancer types.
Uri Greenbaum +7 more
openaire +2 more sources
Advances in chimeric antigen receptor T cells
Current Opinion in Hematology, 2020Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire +2 more sources
Chimeric Antigen Receptors for the Tumour Microenvironment
2020Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option.
Rosemary, Habib +3 more
openaire +2 more sources